期刊文献+

大鼠肺动脉高压动物模型的建立及磷酸二酯酶1C的表达

Establishment of A Pulmonary Arterial Hypertension Model in Rats and Expression of Phosphodiesterase 1C
下载PDF
导出
摘要 目的以左肺切除(PE)+野百合碱(MCT)建立大鼠肺动脉高压(PAH)新生内膜模型,探讨磷酸二酯酶1C(PDE1C)在该模型肺组织中的表达水平及作用。方法采用单纯PE、MCT、PE+MCT(P+M)3种方法建立大鼠PAH模型;检测模型大鼠平均肺动脉压力(mPAP)、中膜厚度百分比、右心肥厚指数(RV/LV+S)比值,观察新生内膜形成和非肌性小动脉肌化程度,比较3种PAH动物模型肺血管重构模式的差异;采用免疫组化检测PDE1C在3种动物模型肺组织中的表达水平。结果 P+M组右肺腺泡内血管出现新生内膜病变,且动物出现严重右心室肥大,肺动脉中膜增厚,平均mPAP和无肌性血管肌化程度较其他模型显著增加。大鼠PAH新生内膜模型PDE1C蛋白表达显著增加(P<0.05)。结论 P+M模型能更好地模拟人类严重PAH的病理改变,是研究梗阻性PAH的最佳动物模型。PDE1C在PAH动物模型肺动脉平滑肌细胞中显著上调,可能成为肺动脉高压治疗的新靶点。 Objective To establish a neointima model of pulmonary arterial hypertension (PAH) in rats by pneumonectomy(PE) and monoerotatine(MCT),and to investigate the expression and function of phosphodiesterase 1C (PDE1C) protein in this PAH model.Methods Three approaches were used to establish PAH model in rats:left lung PE group(PE group),MCT injection group,and MCT injection after PE group (P+M group).Mean pulmonary arterial pressure(mPAP),percentage of media thickness(MT%) and the ratio of right ventricular hypertrophy index (RV/LV+S) of model rats were recorded.Morphological parameters relevant to neointima formation and the muscularization of nonmuscle pulmonary arterioles were observed,and the difference of pulmonary vascular remodeling pattern of the three PAH models was analyzed.The expression of PDE1C was detected in each group by immunohistochemitry.Results The P+M group showed serious lesions in the neointim and right ventricular,and serious right ventricular hypertrophy,and the increasing MT of pulmonary arterials could be seen in the animals.Compared with other groups,P+M group had a significantly higher mPAP and muscularization of nonmuscle arterioles developed significantly.Expression of PDE1C protein increased significantly in the neointima PAH model(P〈0.05).Conclusion P+M model is a good model for simulation of severe PAH in human , which is the best animal model for a study on the obstructive PAH.Up-regulation of PDE1C in pulmonary artery smooth muscle cells of PAH animal model might offer a new target for therapy of PAH in human .
出处 《广西医学》 CAS 2013年第4期418-421,共4页 Guangxi Medical Journal
关键词 肺动脉高压 血管重构 新生内膜 磷酸二酯酶 动物模型 大鼠 Pulmonary hypertension Vascular remodeling Neointima Phosphodiesterase Animal model Rat
  • 相关文献

参考文献10

  • 1Voelkel NF, Quaife RA, Leinwand LA,et al. Right ventricu-lar function and failure : report of a National Heart, Lung,and Blood Institute working group on cellular and molecularmechanisms of right heart failure [ J ] . Circulation ,2006,114(17):1 883 -1 891. 被引量:1
  • 2甘辉立,张健群,张兆光,罗毅,穆军升,周其文,王胜洵,郑斯宏,朱光发,张向峰,刘双.慢性栓塞性肺动脉高压手术与非手术治疗的转归及其临床分型的探讨[J].中华心血管病杂志,2008,36(1):11-15. 被引量:10
  • 3Rich S, Kaufmann E, Levy PS. The effect of high doses ofcalcium-channel blockers on survival in primary pulmonaryhypertension[ J]. N Engl J Med. 1992,327(2) :76-81. 被引量:1
  • 4Botney MD. Role of hemodynamics in pulmonary vascular re-modeling :implications for primary pulmonary hypertension[J]. Am J Respir Crit Care Med, 1999,159(2) :361 -364. 被引量:1
  • 5Nishimura T,Faul JL,Berry GJ,et al. Simvastain attenuatessmooth muscle neointimal proliferation and pumonary hyper-tension in rats[ J]. Am J Respir Crit Care Med,2002,166(10):1 403 -1 408. 被引量:1
  • 6Rybalkin SD,Bomfeldt KE,Sonnenburg WK,et al. Calmodu-lin-stimulated cyclic nucleotide phosphodiesterase ( PDE1C )is induced in human arterial smooth muscle cells of the syn-thetic ,proliferative phenotype [ J]. J Clin Invest, 1997,100(10):2 611 -2 621. 被引量:1
  • 7Mitani Y’Ueda M,Komatsu R,et al. Vascular smooth mus-cle cell phenotypes in primary pulmonary hypertension[ J].Eur Respir J,2001,17(2) :316 -320. 被引量:1
  • 8Rubin LJ. Therapy of pulmonary hypertension:the evolutionfrom vasodilators to antiproliferative agents [ J ]. Am J RespirCrit Care Med,2002,166(10) :1 308 -1 309. 被引量:1
  • 9Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: atarget for therapeutic intervention in pulmonary hypertension[J]. Pharmacol Ther,2002,92( 1):1 -20. 被引量:1
  • 10Wharton J, Strange JW, M0ller GM,et al. Antiproliferativeeffects of phosphodiesterase type 5 inhibition in human pul-monary artery cells [ J ]. Am J Respir Crit Care Med, 2005,172(1) :105 -113. 被引量:1

二级参考文献11

  • 1甘辉立,张健群,陈辉,穆军升,周其文,王胜洵,郑斯宏,张向峰,刘双.肺动脉血栓内膜剥脱术治疗慢性栓塞性肺动脉高压及深低温停循环对其疗效的影响[J].中华医学杂志,2007,87(21):1482-1485. 被引量:15
  • 2Thistlethwaite PA, Mo M, Madani MM, et al. Operative classification of thromboembolic disease determines outcome after pulmonary endarterectomy. J Thorac Cardiovasc Surg, 2002,124: 1203-1211. 被引量:1
  • 3McNeil K, Dunning J. Chronic thromboembolic pulmonary hypertension (CTEPH). Heart,2007, 93 : 1152-1158. 被引量:1
  • 4Jamieson SW, Kapelanski DP. Pulmonary endarterectomy. Current Problems in Surgery,2000,37: 167-252. 被引量:1
  • 5Kim NH. Assessment of operability in chronic thromboembolic pulmonary hypertension. Proc Am Thorac Soc,2006,3: 584-588. 被引量:1
  • 6Carbrol S, Souza R, Jais X. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. J Heart Lung Transplant, 2007,26 : 357-362. 被引量:1
  • 7Reichenberger F, Voswinckel R, Enke B, et al. long-term treatment with sildenafil in chronic thromboembolic pulmonary hypertension. Eur Respir J,2007,30:922-927. 被引量:1
  • 8Bresser P, Pepke-Zaba J, Jais X, et al. Medical therapies for chronic thromboembolic pulmonary hypertension: an evolving treatment paradigm. Proc Am Thorac Soc ,2006, 3:594-600. 被引量:1
  • 9Huges R j, Jais X, Bonderman D, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J,2006, 28 : 138-143. 被引量:1
  • 10甘辉立,张健群,张兆光,周其文,罗毅,穆军升,王胜洵,郑斯宏,张向峰,刘双,朱光发.肺动脉栓塞外科治疗54例临床分析[J].中华外科杂志,2008,46(1):48-51. 被引量:12

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部